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HepatitisBvirus(HBV)-speciﬁcT-cellresponsesareimportantinthenaturalhistoryofHBVinfection.Thenumberofknown
HBV-speciﬁcT-cellepitopesislimited,anditisnotclearwhetherviralevolutionoccursinchronicHBVinfection.Weaimedto
identifynovelHBVT-cellepitopesbyexaminingtherelationshipbetweenHBVsequencevariationandthehumanleukocyte
antigen(HLA)typeinalargeprospectiveclinic-basedcohortofAsianpatientswithchronicHBVinfectionrecruitedinAustralia
andChina(n119).High-resolution4-digitHLAclassIandIItypingandfull-lengthHBVsequencingwereundertakenfor
treatment-naïveindividuals(52%withgenotypeB,48%withgenotypeC,63%HBVeantigen[HBeAg]positive).Statistically
signiﬁcantassociationsbetweenHLAtypesandHBVsequencevariationwereidentiﬁed(n49)at41sitesintheHBVgenome.
Usingpredictionprograms,wedeterminedscoresforbindingbetweenpeptidescontainingthesepolymorphismsandassociated
HLAtypes.Amongtheregionsthatcouldbetested,HLAbindingwaspredictedfor14/18(78%).WeidentiﬁedseveralHLA-
associatedpolymorphismsinvolvinglikelyknownanchorresiduesthatresultedinalteredpredictedbindingscores.SomeHLA-
associatedpolymorphismsfellwithinknownT-cellepitopeswithmatchingHLArestriction.Enhancedviraladaptation(deﬁned
asthepresenceoftherelevantHLAandtheescapedaminoacid)wasindependentlyassociatedwithHBeAg-negativedisease
(P0.003).Thus,HBVappearstobeunderimmunepressureinchronicHBVinfection,particularlyinHBeAg-negativedisease.
G
lobally, infection with hepatitis B virus (HBV) is common,
and despite an effective vaccine, the number of persons with
chronicHBVinfectionisincreasing(9).BroadandeffectiveHBV-
speciﬁcT-cellresponsesarerequiredtoclearacuteHBVinfection
(7, 37), but circulating HBV-speciﬁc T cells are rarely detected in
chronic HBV infection (7, 8). It is therefore unclear whether the
adaptive immune response plays a role in controlling viral repli-
cation in chronic HBV infection and whether changes or adapta-
tions in HBV are selected due to immune pressure.
In individuals with chronic HBV infection, as many as 1011
virus particles are produced per day (21, 30). HBV reverse trans-
criptase lacks proofreading activity, resulting in mutation rates
estimated at 1.5  105 to 5  105 nucleotide substitutions per
site per year in HBV e antigen (HBeAg)-positive individuals (32).
Due to overlapping open reading frames (ORF), HBV genome
evolution is constrained to maintain essential protein functions
requiredforreplication(28).Thereissomeevidencethatchanges
inHBVsequencescanbeselectedduetohostimmunepressure(2,
5, 23) and that the HBV mutation rate is even higher in HBeAg-
negative individuals (15, 33), possibly due to increased immune
pressure prior to HBeAg loss (4, 10, 15) or due to higher levels of
virusreplicationintheabsenceofHBeAg,giventheknowninhib-
itory effect of HBeAg on HBV replication at the level of nucleo-
capsid maturation or stability (13). This suggests that the host
immune response plays an important role in HBV evolution.
The human leukocyte antigen (HLA) molecules determine
how foreign peptides are presented to T cells. Population-based
genetic approaches have identiﬁed statistically signiﬁcant associ-
ations between speciﬁc HLA types and polymorphisms (adapta-
tions) in human immunodeﬁciency virus (HIV) and hepatitis C
virus (HCV) (12, 29, 31, 45). Many HLA-associated viral poly-
morphisms in HIV- and HCV-infected patients were within
knownT-cellepitopes,consistentwithimmunepressure(12,29).
Thesesitesofadaptationweresubsequentlyusedtoidentifynovel
T-cell epitopes for both HIV and HCV (16, 20, 36). In this study,
we examined the relationship between HBV polymorphisms and
speciﬁc HLA types in an Asian population in order to ﬁnd evi-
dence of viral evolution of HBV at a population level and to de-
terminewhetherviraladaptationwasassociatedwithclinicalout-
comes. Additionally, we aimed to use these data to identify
putative novel HBV epitopes in an Asian population.
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 MATERIALS AND METHODS
Subjects. HBV-infected individuals of ethnic Chinese origin were re-
cruited from the Queen Mary Hospital in Hong Kong, China (n  141),
and from St. Vincent’s Hospital (n  51), The Alfred (n  11), and Box
Hill Hospital (n  18) in Melbourne, Australia. Chronic HBV infection
was deﬁned by the presence of detectable HBV surface antigen (HBsAg)
ontwooccasionsmorethan6monthsapart,andallindividualswerenaïve
toantiviraltherapy.AllindividualswereHIVandHCVantibodynegative.
Clinical, biochemical, immunological, and virological details were ob-
tained from prospectively maintained clinic databases and/or retrospec-
tive case record review. The study was undertaken with written informed
consent from each individual, and the study protocol conformed to the
ethical guidelines of the 1975 Declaration of Helsinki, and was approved
by the local ethics committees.
HBV DNA quantiﬁcation. In Melbourne, HBV DNA was quantiﬁed
with the HBV Digene Hybrid Capture II microplate assay (Digene Diag-
nostics, Beltsville, MD) or the Versant HBV DNA 3.0 assay (Siemens
Healthcare Diagnostics, Tarrytown, NY), in accordance with the manu-
facturer’s instructions. The lower limit of detection (LLD) of the Digene
HybridCaptureIImicroplateassaywasapproximately24,912IU/ml,and
that of the Versant HBV DNA 3.0 assay was 357 IU/ml. For samples from
Hong Kong, HBV DNA was quantiﬁed using an in-house TaqMan assay
amplifyingthecoreregion,withanLLDof77IU/ml.Therefore,anLLDof
357 IU/ml was used for all individuals. Alanine aminotransferase (ALT)
levels were considered increased if they were 40 U/liter for the Box Hill
Hospital and Alfred cohorts, 35 U/liter for the St. Vincent’s cohort, or
80 U/liter for the Hong Kong cohort.
PCR and sequencing. HBV DNA was extracted from 200 l of serum
usingtheQIAampDNAMinikit(Qiagen,Dusseldorf,Germany)accord-
ing to the manufacturer’s instructions. The puriﬁed DNA was eluted in a
ﬁnal volume of 50 l. HBV DNA was ampliﬁed by PCR using the Pico-
Maxxhigh-ﬁdelityPCRsystem(Stratagene,LaJolla,CA)andthemethod
adapted from Günther et al. (14). The sequencing assay has an LLD of
roughly2,000IU/ml,becauseahigh-ﬁdelityenzymeisrequiredtoamplify
arelativelylargepieceofDNA.Sampleswithviralloadsgreaterthan2,000
IU/mlgenerallyrequiredonlyoneroundofPCR.AsecondroundofPCR
was performed for samples with low viral loads (between 357 and 2,000
IU/ml) by amplifying two overlapping DNA fragments with primers P1
and 1798* (nucleotides [nt] 1799 to 1820) (3=-CCAACTGCATGGCCTG
AGGATG-5=) and primers JM* (nt 1676 to 1696) (3=-TTGGGGTGGAG
CCCTCAGGCT-5=) and P2, using 2 l of the ﬁrst-round product as the
template with 25 cycles. Consensus sequences were determined for each
genotypeandHBVprotein,andtheaminoacids(aa)foreachproteinand
genotype were compared in order to determine percentages of difference
per genotype and protein. Polymorphism was deﬁned as the overall per-
centage of nonconsensus amino acids at a particular residue.
Cloning. Cloning was undertaken for mixed populations (those for
which the secondary peak was 20% of the main peak) in 14 patients (1
with genotype B and 13 with genotype C). Cloning was performed using
theTopoXLTAcloningkit(Invitrogen,Mt.Waverley,Australia),andon
average, 5 clones were selected and 2 to 4 clones were sequenced for each
patient.Thesequencesoftheindividualclonesforeachsubjectwerethen
used in the analysis.
HLA typing. High-resolution HLA class I (HLA-A, -B, and -C) and II
(HLA-DRB1) typing was performed as described previously (48). Allele
assignments (Table 1) were made using the Assign program (Conexio
Genomics, Fremantle, Australia). This program utilizes the database of
HLA allele sequences on the IMGT/HLA website (http://www.ebi.ac.uk
/imgt/hla/). Generally, ambiguities were resolved following sequencing
with allele-speciﬁc subtyping primers. However, for a few individuals,
identity at exons 2 and 3 was consistent with the presence of rare alterna-
tiveandnullalleles,andintheserarecases,thealleleassignmentwasbased
onthemostcommonlyexpressedalleleandhaplotypecombinationinthe
relevant population (http://www.allelefrequencies.net/).
Phylogeneticanalysis.DeducedHBVaasequencesfromthedifferent
proteins were aligned using ClustalX. Phylogenetic analysis of the HBV
polymerase (Pol) protein was carried out using the neighbor-joining
method based on the p-distance model with pairwise deletion and the
modiﬁed Nei-Gojobori method (49). The mean genetic distances (mean
numbersofdifferences/sequencelength)betweenandwithingenotypeB-
and genotype C-infected individuals were determined using the same
alignments. All analyses were performed using MEGA, version 3.1 (44).
Statisticalmethods.(i)AssociationbetweenspeciﬁcHLAallelesand
viral polymorphism. Statistical analysis of speciﬁc associations between
HLA alleles and viral polymorphism, including assessment of any impact
of founder effects, followed the methods described by Rauch et al. (36).
Analyses were carried out in TIBCO Spotﬁre S (Tibco Software, Inc.).
BecausethisstudywastheﬁrsttoexamineHBVviraladaptationusingthis
approach,anonconservativecutoffwasusedtoidentifyviraladaptations,
based on a Fisher P value of 0.05 and a cluster-corrected Mantel-
Haenszel P value of 0.1. While false discovery rates and associated
q-values as described by Rauch et al. (36) can be obtained for these data,
the relatively small sample sizes precluded sensible estimation, and they
are not reported here. Odds ratios (OR) for association were compared
across genotypes via log-linear models.
(ii) Correlation between host viral adaptation and clinical parame-
ters.ForallHBVproteins,anindividual’s“adaptationscore”wasdeﬁned
as the number of residues for which the individual had at least one of the
relevant HLAs with a deﬁned association and the escaped aa was present.
Relationships between the adaptation score and the clinical parameters
ALT level, HBeAg status, and HBV DNA level were assessed via analyses
appropriate to the nature of the data; the continuous variable ALT level
TABLE 1 Frequencies of the most common HLA types in an HBV-
infected Asian cohort and their associations with genotypes B and C
HLA type
No. (%) of patients with:
Genotype B Genotype C
A*
1101 28 (48) 19 (37)
3303 14 (24) 10 (19)
0201 10 (17) 12 (23)
2402 12 (21) 14 (27)
0203 6 (10) 14 (27)
0207 12 (21) 8 (15)
B*
4001 17 (28) 17 (32)
1502 20 (33) 9 (17)
4601 19 (31) 8 (15)
1301 8 (13) 8 (15)
3802 4 (7) 10 (19)
5801 8 (13) 6 (11)
Cw*
0702 23 (38) 25 (47)
0801 25 (41) 13 (25)
0102 22 (36) 12 (23)
0304 9 (15) 16 (30)
0302 8 (13) 6 (11)
DRB1*
0901 19 (32) 19 (35)
0803 6 (10) 11 (21)
1602 7 (12) 10 (19)
0301 6 (10) 6 (11)
0701 5 (8) 7 (13)
1401 7 (12) 3 (6)
Desmond et al.
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 was analyzed (on the log scale) via linear regressions, categorical HBeAg
status via Fisher tests, and HBV DNA level by using Cox regression to
accommodate right censoring of the higher values.
Peptide-HLAligation.PutativenovelHLAclassIandIIepitopeswere
screened using the BIMAS (34), SYFPEITHI (35), and Immune Epitope
(47)databasesofpredictivealgorithmsofpeptide-HLAinteraction(when
the relevant HLA type was available in the databases). Cutoffs for “good”
epitopes were set at scores of 18 and 50 for SYFPEITHI and BIMAS,
respectively, as described previously (36). These algorithms estimate the
strength of ligation between a speciﬁc aa sequence and a deﬁned HLA
type. These algorithms have been validated previously by comparing the
predictivebindingofaparticularaa,basedonitssidechainstructure,with
its actual binding (34). For each open reading frame, screening was un-
dertaken by testing HLA-sequence binding using the aa sequences sur-
roundingasiteassociatedwithaspeciﬁcHLAallele(13aaforHLAclass
I and  17 aa for HLA class II).
RESULTS
Studyrecruitmentandparticipants.Patientrecruitmentandde-
mographic characteristics are described in Fig. 1 and Table 2.
HBVpolymorphismrate.Thepolymorphismrateateachres-
idue was calculated as the proportion of patients infected with
HBVwhohadanonconsensusresidueatthatsite.TheHBVpoly-
morphismratedifferedateachresidueacrossthegenome,ranging
from 0% to 49% for genotype B and 0% to 53% for genotype C
(Fig.2).Wethencomparedthedegreeofaavariationbetweenthe
consensusgenotypeBandCsequencesforeachHBVproteinand
found differences at 91/843 (10.8%) sites for Pol, 49/400 (12.2%)
sites for pre-S, 17/154 (11%) sites for X protein, and 0/211 (0%)
sites for core. The difference for core between genotypes B and C
was lower than those for the other proteins (P  0.00001).
The intergenotype mean genetic distance (0.09) was greater than
the intragenotype mean genetic distance (0.03). The synonymous
and nonsynonymous genetic distances within each genotype across
the proteins were similar, reﬂecting the maintenance of the basic
structure and function of the proteins within both genotypes (Table
3).AswithHCV(36),thesegenotypedifferencesarelikelytohavean
impact on potential sites of escape from HLA-restricted immune
pressure across the genome. Therefore, all subsequent analyses were
performed separately for genotypes B and C.
Phylogenetic analysis. We then analyzed all HBV sequences
in order to determine the relatedness of the sequences to each
FIG 1 Patient recruitment and exclusions. VL, viral load; ve, positive.
TABLE 2 Demographic characteristics of individuals included in the ﬁnal analysis
Patient characteristic
Value
Genotype B Genotype C Total
No. of patients 62 57 119
No. (%) male 34 (55) 41 (72) 75 (63)
No. (%) HBeAg positive 35 (57) 40 (70) 75 (63)
Median (range) ALT concn (IU/liter) 47 (8-500) 65 (24-591) 59 (8-591)
No. immunotolerant/no. immunoactive (%)a 24/11 (69) 31/9 (78) 55/20 (73)
Median (range) HBV DNA concn (IU/ml) 1.20  107 (446-1.7  107) 2.69  105 (689-1.7  107) 2.85  106 (446-1.7  107)
No. (%) with subgenotype:
1 1 (2) 12 (21)
2 44 (71) 14 (24)
3 4 (6)
4 13 (21)
5 31 (55)
a Immunotolerant patients are HBsAg positive and HBeAg positive, with an ALT level less than twice the upper normal limit. Immunoactive patients are HBsAg positive and
HBeAg positive, with an ALT level more than twice the upper normal limit. The sum of immunotolerant and immunoreactive patients as a percentage of all patients is given in
parentheses.
Viral Adaptation and Immune Response to HBV
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 other. Phylogenetic analysis revealed clustering within the
main genotype, with strong bootstrap support (Fig. 3). There
was further clustering of sequences within each speciﬁc geno-
type,mainlyrepresentingsubgenotypes.Themethodsusedac-
counted for the clustering within the tree, and therefore, we
concluded that any HLA-associated viral polymorphisms were
not likely to be due to aa changes speciﬁc to a subcluster. The
lack of clustering (outside the genotype and subgenotypes)
conﬁrmed that sequences from subjects recruited from each
site could be combined for HLA/polymorphism analysis but
that genotype B and C sequences should be analyzed separately
(as discussed above).
HLA-associated viral polymorphisms representing putative
viraladaptations.Weidentiﬁed49statisticallysigniﬁcantasso-
FIG 2 HBV polymorphism rates for patients infected with genotype B or C. The x axis shows the aa position for each HBV protein. Vertical bars indicate the
proportions of sequences with nonconsensus residues for genotype B (above the horizontal line at zero on the y axis) and genotype C (below the horizontal line
at zero on the y axis) for Pol (A), pre-S (B), core (C), and X protein (D).
TABLE 3 Mean genetic distances within and between HBV genotypes
Comparison
No. of substitutions/sitea for the following protein:
Pol X Core Pre-S
Synonymous Nonsynonymous Synonymous Nonsynonymous Synonymous Nonsynonymous Synonymous Nonsynonymous
Within genotype
Genotype B 0.047 0.016 0.022 0.018 0.043 0.011 0.036 0.01
Genotype C 0.049 0.015 0.023 0.015 0.048 0.011 0.034 0.012
Between genotypes 0.174 0.058 0.075 0.061 0.109 0.012 0.135 0.067
a Calculated as the mean number of synonymous differences per synonymous site or the mean number of nonsynonymous differences per nonsynonymous site, based on pairwise
comparison of all sequences within and between genotypes. “Synonymous site” means that nucleotide changes would not result in an amino acid change, while “nonsynonymous
site” means that nucleotide changes would result in an amino acid change. A modiﬁed Nei-Gojobori method (49) using the p-distance model was used to perform calculations.
Desmond et al.
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 ciationsbetweentheHLAtypeandviralpolymorphisms.These
included 37 associations for genotype B (18 for Pol, 6 for the
envelope protein, 8 for core, and 5 for X protein), correspond-
ing to 30 residues, and 12 associations for genotype C (3 for
Pol, 2 for the envelope protein, 3 for core, and 4 for the X
protein), corresponding to 11 residues (Table 4). Four of the
associations had an OR of 1, indicating that the consensus
sequencehadtheadapted(or“escaped”)aa(12,29),andinone
case, two different residues occurred with equal frequency in
the consensus sequence.
There was clustering of associations (involving different HLA
types and genotypes) at certain amino acids. For example, the
polymorphism at Pol aa 470 was associated with HLA-A*0201
(genotype B) and HLA-A*2402 (genotype C) (Table 4). Two or
more HLA types were associated with polymorphisms at Pol aa
104 (genotype B) and 602 (genotype B), core aa 89 (genotype B)
and 180 (genotype B), and X protein aa 131 (genotype C), 47
(genotype B), and 143 (genotype B).
HBV genotype and HLA-associated viral polymorphisms.
There was no overlap in speciﬁc 2-digit or 4-digit HLA-
associated viral polymorphisms, and overall, there was no evi-
dence of a difference in HLA distribution between genotypes B
and C (P  0.1). However, some HLA types were overrepre-
sented in genotype B (including HLA-A*0206 [P  0.038],
HLA-B*1502 [P  0.034], and HLA-DRB1*1202 [P  0.04]),
andotherswereunderrepresentedingenotypeB(HLA-A*0203
[P  0.02]). We then examined the frequency of variation for
each of the 49 HLA (4-digit)-associated viral polymorphisms
(corresponding to 41 sites) for the alternate genotype. Ten of
the49(20%)HLAassociationscouldnotbecomparedbetween
the genotypes, since fewer than 5 patients infected with the
alternate genotype carried the speciﬁc HLA type. Of the re-
maining 39 residues that could be compared, 12 (31%) were
completely conserved in the alternate genotype, even though
the speciﬁc HLA type was present in patients with that geno-
type. Furthermore, 21 of the 41 (51%) sites differed in the
consensus sequence between the genotypes. The differences in
the polymorphism and escape pattern between genotypes are
highlighted in Fig. 4.
HLA-associated viral polymorphisms within known HBV
T-cell epitopes. We then looked to determine if the HLA-
associated viral polymorphisms we identiﬁed were located in
known HBV epitopes. We examined all published epitopes from
all HBV genotypes (summarized and reviewed in reference 8).
When we examined prior reports that also used 4-digit HLA typ-
ing, we identiﬁed two HLA-associated viral polymorphisms
within previously published HBV epitopes with the same HLA
restriction. The HLA-A*0201-associated polymorphism at aa 195
within the genotype B envelope protein occurred within the
knownHLA-A*0201-restrictedepitopespre-S1aa188to196(Saa
14to22)(7,42)andpre-S1aa194to202(Saa20to28)(22)(Fig.
4 and 5; Table 5) (position 195; OR, 15; conﬁdence interval [CI],
1.3 to 264; P  0.01). The pre-S1 aa 194-to-202 (S aa 20-to-28)
epitope has been demonstrated to elicit speciﬁc cytotoxic
T-lymphocyte responses in HLA-A2 Chinese patients with a
pre-S1 aa 194-to-202 (S aa 20-to-28) sequence identical to that of
our patients (22). Pre-S1 aa 195 involved the primary anchor po-
sition within the HLA-A*0201 T-cell epitope, where mutation
could potentially abrogate HLA binding. The additional HLA-
A*0201-associatedpolymorphismataa384withinthegenotypeC
envelope protein occurred within the known HLA-A*0201-
restrictedepitopespre-S1aa381to390(Saa207to216)(38)and
pre-S1 aa 382 to 390 (S aa 208 to 216) (18) (Fig. 5; Table 5) (posi-
tion384;OR,5;CI,0.8to35;P0.04).Thepre-S1aa382-to-390
(S aa 208-to-216) epitopes (18) had been identiﬁed in genotype
C-infected individuals.
When we examined the list of HLA associations based on
2-digittyping(datanotshown),wefoundafurtherthreepossible
HLAallele-speciﬁcviralpolymorphismsthatﬂankedknownCD8
T-cell epitopes, including HLA A*11-associated polymorphisms
at core aa 116 (OR, 7.3; CI, 1.1 to 479; P  0.01) and aa 126 (OR,
5.3; CI, 0.8 to 356; P  0.096) and an HLA A*02-associated poly-
morphism at X protein aa 143 (OR, 0.05; CI, 0 to 0.6; P  0.006).
The association between HLA A*02 and X protein aa 143 favored
conservation of the wild-type sequence. These associations did
notreachstatisticalsigniﬁcanceinthe4-digitanalysis,mostlikely
becausetheHLA-A*11andHLA-A*02alleleshavemorethanone
mainsubtype,whichwereanalyzedseparatelyinour4-digitanal-
ysis.
These data therefore support the validity of our population-
based approach to identifying novel T-cell epitopes.
HLA-associated viral polymorphisms within putative novel
HBV T-cell epitopes. In order to determine whether HLA-
associated viral polymorphisms not located within known
epitopes were of potential biological signiﬁcance, we used the
Web-based epitope prediction programs (SYFPEITHI, BIMAS,
and the Immune Epitope database) to determine predicted bind-
ing of the viral sequence and associated HLA type. Predicted pu-
tative epitopes were identiﬁed within all HBV proteins (Table 5).
In addition, we identiﬁed putative aa escape polymorphisms that
were associated with lower predicted HLA binding in several of
these epitopes, many located at likely anchor residues (Table 5).
Although not yet tested in functional assays using T cells from
patients with chronic HBV, these data provide strong supportive
evidence that many of the HLA-associated polymorphisms newly
identiﬁedinthisstudyarelikelytobewithinHBVT-cellepitopes.
Hostviraladaptationandclinicalparameters.Wethenasked
whether the degree of adaptation of HBV was associated with any
clinicalparametersatapopulationlevel.Wedeﬁnedadaptationas
FIG 3 Phylogenetic analysis of polymerase amino acid sequences for patients
recruited from Hong Kong (HK) and Victoria, Australia (VIC).
Viral Adaptation and Immune Response to HBV
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 TABLE 4 Associations between amino acid residues and HLA types for individuals infected with genotype B or genotype Ca
Proteinb Residue HLA Consensusc OR CI P
Genotype B
Pol 17 A*1102 E 11 1.04–167 0.023
35 DRB1*1202 R 17 1.4-inﬁnity 0.009
73 B*4001 K 0.1 0.00–0.60 0.005
93 DRB1*1201 K 10 1.17–702 0.017
104 B*4601 N 6.4 1.28–49 0.010
104 A*0207 N 5.0 0.88–31 0.036
104 DRB1*0901 N 4.8 0.94–30 0.048
246 A*0207 R 6.6 0.96–56 0.028
266 A*1101 H 14 1.03-inﬁnity 0.023
284 A*0207 A 6.6 0.96–56 0.028
470 A*0201 N 11 1.73–706 0.003
480d DRB1*0901 N 4.4 1.21–20 0.021
568 DRB1*1602 A 15 2.24–219 0.002
602 A*0206 S 8.7 1.36–116 0.010
602 C*0801 S 3.9 1.03–18 0.033
678 A*1101 S 4.0 0.91–29 0.049
692 DRB1*0701 P 7.7 0.80–112 0.040
743 DRB1*0901 K 6.0 1.38–34 0.012
Core 78 A*0206 S 8.6 0.89–92 0.033
89 A*1101 L 0.1 0.0–0.86 0.023
89 DRB1*1602 L 10 1.02–129 0.024
106 B*4001 E 7.4 1.15–100 0.016
116 B*4001 S 0.1 0.00–1.08 0.044
142 B*4601 E 7.8 0.89–539 0.034
180 A*1102 R 8.5 0.88–127 0.033
180 A*1101 R 5.0 0.99–61 0.035
Pre-S 68 A*0206 T 7.7 1.22–103 0.014
195e A*0201 L 15 1.31–264 0.013
214 A*1101 N 5.0 0.99–61 0.035
250 B*1301 C 9.0 0.97–90 0.027
335 A*1101 Y 16 1.18-inﬁnity 0.016
387 DRB1*1602 M 15 2.24–219 0.002
X 47 A*0201 T 8.7 0.90–129 0.032
47 C*1502 T 11 0.67–145 0.049
87 DRB1*0701 R 0.1 0.00–0.92 0.020
143 A*1101 C 17 1.34-inﬁnity 0.022
143 DRB1*1501 C 8.8 0.91–95 0.031
Genotype C
Pol 470 A*2402 Y 5.4 0.76–42 0.050
584 B*3802 N 8 1.23–530 0.021
841 C*0102 R 5.9 0.80–51 0.044
Core 15 A*2402 P 7.3 0.93–76 0.030
113 DRB1*0405 L 7.9 0.76–98 0.045
129 DRB1*1202 L 6.9 0.97–101 0.027
Pre-S 227 DRB1*0803 L 9.9 1.52–91 0.007
300 A*0203 I 7.5 1.08–76 0.020
384e,f A*0201 N 5 0.83–35 0.042
X 36 B*1502 T 6.3 1.07–44 0.020
42 A*3303 S 7.9 0.79–120 0.042
131 C*0801 I 6.7 0.85–70 0.037
131 DRB1*0901 I 8.2 1.24–117 0.013
a Residue, location of the polymorphism; consensus, the amino acid at that site in the consensus sequence. The odds ratio (OR), conﬁdence interval (CI), and P values represent
associations between the 4-digit HLA type and the presence of a consensus versus nonconsensus amino acid.
b Pol, polymerase; pre-S, envelope; X, X protein.
c A, alanine; R, arginine; N, asparagine; C, cysteine; E, glutamic acid; H, histidine; I, isoleucine; L, leucine; K, lysine; M, methionine; P, proline; S, serine; T, threonine; Y, tyrosine.
d Amino acids N and D occur with equal frequency.
e HLA-associated viral polymorphism within a known HBV T-cell epitope. The HLA allele matched the known HLA restriction of the epitope.
f The association just fails the Mantel-Haenszel condition and is included for reference.
Desmond et al.
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 thenumberofresiduesforwhichtheindividualhadatleastoneof
the relevant HLAs with a deﬁned association and the putative
escapedaawaspresent.AmongpatientsinfectedwithgenotypeB,
we found that adaptation was signiﬁcantly lower in HBeAg-
positive than in HBeAg-negative patients (P  0.0155) (Fig. 6).
This difference remained signiﬁcant after adjustment for gender,
recruitment site, ALT level, and HBV DNA level (P  0.001).
Among patients infected with genotype C, we also observed lower
adaptation in HBeAg-positive than in HBeAg-negative patients, but
thisdifferencedidnotreachsigniﬁcanceinanunadjustedanalysis(P
 0.15) (Fig. 6). However, after adjustment for gender, recruitment
site, and HBV DNA level, lower adaptation was signiﬁcantly associ-
FIG4 Genotypevariationwithinenvelopeepitopes.ShownaredifferentvariationpatternsforgenotypesBandCwithinthepublishedHLA-A0201-restricted
envelope epitopes pre-S1 aa 188 to 196 (S aa 14 to 22) (7, 44) and pre-S1 aa 194 to 202 (S aa 20 to 28) (33) containing an HLA-A0201-associated viral
polymorphismsite(position384;OR,5;CI,0.8to35.3;P0.04[Table4]).Theproportionofnonconsensusresidueswithinandﬂankingtheepitopeisindicated
for individuals carrying the HLA-A0201 allele (ﬁlled bar) and for those not carrying this HLA allele (open bars). This likely reﬂects divergent cellular immune
pressuresactingonthevirus.BoldfaceresiduesrepresentthesigniﬁcantHLA-associatedaminoacidpolymorphismsites.Thepublishedepitopeisshownabove
each graph. SYFPEITHI scores for consensus amino acids are given in parentheses.
FIG 5 Associations between HBsAg amino acid polymorphisms and HLA alleles. Signiﬁcant (P  0.05) associations of HLA alleles with viral polymorphisms
within HBsAg may mark relevant immunological sites within the virus. Abbreviations: pre-S1, envelope gene encoding the large surface glycoprotein; pre-S2,
envelope gene encoding the middle surface glycoprotein; HBsAg, hepatitis B surface antigen; tp, terminal protein; rt, reverse transcriptase; rh, RNase H. (A)
Published HLA class I-restricted epitopes (9). (B) Published HLA class II-restricted epitopes (9). NA, not available. (C) Speciﬁc HLA associations with viral
mutations within the HBsAg (upper row, genotype B; lower row, genotype C) whereby variation from the consensus amino acid is overrepresented in the
HLA-positive group. HLA alleles are shown at the positions of association, with odds ratios given below. Associations within HLA-matched published epitopes
are in boldface. (D) Consensus sequences of HBsAg amino acids for genotypes B (upper row) and C (lower row). Sequences are numbered from the start of
HBsAg(upperline)andfromthestartofthesurfacegene(lowerline).Wefoundhighlysigniﬁcantassociations(P0.05)betweenHLAA0201andEnvresidues
195 and 384. These matched known published HLA A0201 epitopes.
Viral Adaptation and Immune Response to HBV
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 TABLE 5 Associations between amino acid residues and HLA types within potential novel epitopes
Proteina and residues Reference(s) Genotype HLA Sequenceb Syc
Pol
261–269 B A*1101 GSGPTHNCA 14
GSGHTHICA 17
GSGHTYNCA 13
GSGPTNNCA 14
GSGHTCNCA 13
466–474 B A*0201 RIINNQHRT 15
RIINDQHRT 15
RIINHQHRT 15
671–679 B A*1101 PTYKAFLSK2 1
PTYKAFLHK2 5
PTYKAFLRN1 5
PTYKAFLNK2 5
682–696 B DRB1*0701 LNLYPVARQRPGLCQ 16
LNLYPVVRQRPGLCQ 10
LNLYPVARQRSGLCQ 16
Core
105–113 B B*4001 LEDPASREL 23
LDDPASREL 13
174–182 B A*1101 TTVVRPRGR 20
TTVVRRRGR 19
TTVVRQRGR 19
TTVIRQRGR 18
Pre-S
188–196d 7, 43 B A*0201 VLQAGFFLL2 3
VLQAGFFSL1 2
194–202d 7 B A*0201 FLLTKILTI 29
FSLTKILTI 19
210–218 B A*1101 WTSLNFLGG 15
WTSLSFLGG 15
335–343 B A*1101 YLWEWASVR 16
FLWEWASVR 16
SLWEWASVR 19
381–390d 38 C A*0201 NILNPFLPLL 25
NIVKPFIPLL 23
NILSPFLPLL 25
NILKPFLPLL 25
382–390d 7, 18, 43 C A*0201 ILNPFLPLL 31
IVKPFIPLL 23
ILSPFLPLL 30
ILKPFLPLL 29
X
44–53 B A*0201 VVPTDHGAHL 17
AVPPDHGAHL 20
LVPADHGAHL 18
AVPSDHGAHL 18
76–90 B DRB1*0701 ARRMETTVNAHRNLP 22
ARRMETTVNAHGNLP 22
ARRMETTVNAHWNLP 28
135–143 B A*1101 GGCRHKLVC 8
GGCRHKLVR 16
138–152 B DRB1*1501 RHKLVCSPAPCNFFT 18
RHKLVRSPAPCNFFT 18
a Pol, polymerase; pre-S, envelope.
b Boldface indicates the HLA-amino acid association.
c Sy, SYFPEITHI score based on algorithms of predicted peptide-HLA interaction.
d HLA-associated viral polymorphism within a known HBV T-cell epitope.
Desmond et al.
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 ated with HBeAg-positive status, as we found for genotype B (P 
0.02). Combined analysis of genotypes B and C indicated no differ-
ence between the genotypes for an association between HBeAg and
adaptation (P  0.2). In the combined analysis, HBeAg-positive
status and adaptation were again strongly associated (P  0.003).
There was no evidence that adaptation was associated with
lower HBV DNA levels in genotype B (P  0.45) or genotype C
(P  0.5) (Fig. 6). There was no signiﬁcant relationship be-
tween adaptation and ALT levels for either genotype B or ge-
notype C (P, 0.72 and 0.17, respectively) (Fig. 6).
FIG 6 Associations between the adaptation score and clinical parameters for patients infected with genotypes B (left) and C (right). The parameters assessed
included HBeAg status (A), ALT level (B), and HBV DNA load (C). (A and B) Data are shown as box-and-whisker plots, where the middle line represents the
median;theedgesofeachboxrepresentthe25thand75thpercentiles;andthewhiskersrepresenttherange.(C)Dataareplottedastheproportionofcases(yaxis)
exceeding the corresponding log viral load on the x axis (Kaplan-Meier plots).
Viral Adaptation and Immune Response to HBV
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 DISCUSSION
We performed full-length HBV sequencing and high-resolution
HLA typing for a large cohort of Asian individuals chronically
infected with HBV genotype B or genotype C and identiﬁed 49
statistically signiﬁcant associations between viral polymorphisms
and HLA type, including associations within previously deﬁned
HLA-matched T-cell epitopes. Novel epitopes involving all HBV
proteins and potential escape mutations were also identiﬁed. Of
these putative epitopes, we were able to predict HLA binding for
14/18(78%)associations,andweidentiﬁedpolymorphismsasso-
ciated with reduced binding. Polymorphisms occurred in likely
anchor residues, consistent with other escape mutations (6, 39).
Finally, we found a signiﬁcant association between viral adapta-
tion within a host and the absence of HBeAg. Taken together,
these data demonstrate that HBV is under signiﬁcant immune
pressure at a population level and that this is most prominent in
HBeAg-negative individuals.
This is the ﬁrst large population-based study aimed at iden-
tifying novel HBV epitopes in a cohort of Asian individuals,
who have HLA types vastly different from those of Caucasians.
The majority of known HBV HLA class I-restricted epitopes
have been identiﬁed in individuals with HLA-A2. However,
75% of individuals with chronic HBV infection reside in Asia
(19, 24), where HLA-A24 is the most common HLA class I
allele (43). Furthermore, HLA-A11 is present in 52% of Chi-
nese individuals and 14% of Caucasians, and HLA-B40 is pres-
ent in 32% of Chinese individuals and 15% of Caucasians (25)
(results consistent with those obtained in this study [Table 1]).
Additionally, there are substantial differences in allele sub-
types. More than 95% of Caucasians with HLA-A2 have HLA-
A0201, whereas subtypes HLA-A*0203, HLA-A*0206, and
HLA-A*0207 are present in 23%, 10%, and 45% of HLA-A2
individuals of Chinese origin, respectively (17).
Given the degree of constraint on HBV viral evolution,
largely as a result of overlapping ORF, we found a surprisingly
high degree of viral sequence variability, and this differed for
genotype B and genotype C. The mean intragenotype genetic
distance for genotypes B and C was 0.03, similar to the intrag-
enotype value of 0.05 previously reported for nonstructural
protein3ofHCVgenotype1sequences(12,36).Nonstructural
protein3isthemostconservedofthenonstructuralproteinsin
HCV.TheintergenotypegeneticdistanceforHCVgenotypes1
and 3 was much higher than that observed for HBV (0.20 for
HCV versus 0.09 for HBV), reﬂecting greater diversity overall
forHCVthanforHBV.Furthermore,insupportofthehypoth-
esis that viral escape is driven by host immune pressure and is
restricted by viral (genotype) characteristics, we found sub-
stantial differences in the consensus sequences for HBV geno-
typesBandCthatmayabrogateHLAbindingtocriticalanchor
residues within viral epitopes (Fig. 4).
We identiﬁed HLA-associated viral polymorphisms that
were located within previously described epitopes, providing
support for this population-based methodology. In a recent
study of New Zealand Tongans with chronic hepatitis B (CHB)
with known speciﬁc HLA types (mainly HLA-B*4001 and
HLA-B*5602 in patients with genotype C and D infections), 13
sites in the HBV genome under signiﬁcant positive selection
pressure were identiﬁed, and 5 of these sites were associated
with a speciﬁc HLA type (1). One of these signiﬁcant associa-
tions was between HLA-B*4001 and position 106 (equivalent
to position 77 in reference 1), the same association found in
our cohort, but by use of a different approach, identifying ad-
aptation rather than selection.
After adjusting for gender, recruitment site, and HBV DNA
level, we found signiﬁcantly lower adaptation in HBeAg-
positiveindividualsforbothgenotypesBandC.Theseﬁndings
are consistent with those of another study comparing HBV
sequences in individuals over a 20- to 35-year period, where
HBeAg-positive asymptomatic carriers with very high levels of
HBV DNA had highly conserved nucleotide sequences (33). In
contrast, mutations were seen in HBeAg-negative carriers
(mean, 20 mutations) and were distributed over all regions of
the viral genome, occurring more frequently in putative CD8
T-cellepitopes(33).Onepotentialinterpretationoftheseﬁnd-
ings and ours is that in the absence of HBeAg and its “suppres-
sive”effectontheimmuneresponse,theHBVsequenceevolves
more rapidly (26, 27, 46). HBeAg leads to reduction of toll-like
receptor-2 expression on monocytes (40) and inefﬁcient re-
leaseoftheinﬂammatorycytokinetumornecrosisfactoralpha.
This promotes an imbalance of T helper 1 (Th-1)/Th-2 re-
sponses, the production of anti-inﬂammatory cytokines, such
as interleukin 4 (IL-4) and IL-10, and the suppression of
HBeAg/HBcAg-speciﬁc CD8 T-cell responses (11). This
“suppressive” cytokine proﬁle is reversed following serocon-
version from HBeAg to HBV e antibody (HBeAb), leading to
increases in IL-12 and gamma interferon levels (a Th-1 cyto-
kine proﬁle), which may enhance CD8 T-cell function (41).
Increased activity of the innate and adaptive immune system
during the HBeAg-negative phase may therefore allow for
increasedimmunepressure,leadingtoanaccumulationofmu-
tations due to immune escape (4, 10, 15). However, this inter-
pretationcanbedirectlyaddressedonlybyexaminingepitope-
speciﬁc responses and potential speciﬁc escape mutations over
time prior to and following HBeAg seroconversion, which we
were unable to do in this study.
We were surprised not to identify an association between ad-
aptation and other clinical parameters, such as the HBV DNA
load.GiventhatHBVhasasmallandcompactgenomewithmul-
tiple overlapping reading frames, any changes in one protein will
lead to changes in another protein (that shares the overlapping
reading frame). These secondary changes could potentially alter
ﬁtnessandthereforemaynotnecessarilyresultinachangeinHBV
DNA load.
Our study had several limitations. First, despite the large
sample size, our study had limited power to detect HLA-
associated viral polymorphisms for rare HLA alleles. Second,
although we checked for phylogenetic relatedness, we cannot
exclude the possibility that in some instances an association
betweenanHLAalleleandviralpolymorphismmaybesecond-
ary to founder effects (3). Third, we identiﬁed putative
epitopes and escape mutations only by using epitope predic-
tion programs. Functional analysis to determine the presence
of epitope-speciﬁc CD8 T cells in HLA-matched individuals
withchronicoracuteHBVinfectionswillbeneededtoconﬁrm
the immunogenicity of these predicted epitopes. Changes in
HLA binding in the presence and absence of the identiﬁed
polymorphism should also be examined by functional testing.
These experiments are under way. Fourth, to demonstrate true
viral adaptation or immune evasion at the time of HBeAg se-
Desmond et al.
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 roconversion, it would be best to assess this in a longitudinal
cohort, which was not possible with our current cohort. Fi-
nally, in this study, we assessed HBV DNA only from plasma,
althoughitispossiblethatquasispeciesvariationoradaptation
may be different in HBV DNA from infected hepatocytes,
whereantigenpresentationlikelyoccurs.Analysisandcompar-
ison of plasma- and liver-derived HBV sequences would be
important in future studies.
We have carried out a comprehensive analysis of viral poly-
morphismsandtheirassociationswiththeHLAtypeacrossthe
fullHBVproteome,withadjustmentforpotentialphylogenetic
relatednessbetweenviralsequencesandlinkagedisequilibrium
between coinherited HLA alleles. We showed differences in
patterns of viral adaptation to HLA-restricted immune pres-
surebetweenHBVgenotypesBandC.Greaterviraladaptation
was observed in HBeAg-negative individuals, consistent with
the concept that the transition from HBeAg-positive to
HBeAg-negative disease is associated with signiﬁcant immune
pressure on the virus. Despite the low frequency of circulating
HBV-speciﬁc T cells, there is evidence that HBV is under sub-
stantial immune pressure. Understanding key epitopes associ-
ated with immune pressure may potentially lead to new thera-
peutic strategies for the management of chronic HBV
infection.
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